<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Seasonal influenza in children: Prevention with antiviral drugs
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Seasonal influenza in children: Prevention with antiviral drugs
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Seasonal influenza in children: Prevention with antiviral drugs
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Flor M Munoz, MD, MSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3974615497">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Influenza is an acute respiratory illness caused by influenza A or B viruses, and rarely influenza C viruses. It occurs in outbreaks worldwide every year, mainly during the winter seasons in temperate climates.
        </p>
        <p>
         Influenza usually is an acute, self-limited, and uncomplicated disease in healthy children, but it can be associated with severe morbidity and mortality. Certain groups of children are at increased risk of severe or complicated influenza infection  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Although immunization is the most important public health measure for the prevention of influenza infection, not all children can receive influenza immunization or have an adequate response to immunization. Chemoprophylaxis with antiviral drugs is an adjunct or alternative to immunization for children who cannot be vaccinated, children expected to have a poor response to immunization, or children who have not had time to respond to immunization.
        </p>
        <p>
         The prevention of influenza in children with antiviral drugs will be presented here. Influenza vaccination in children; the clinical features, diagnosis, and management of influenza in children; and the prevention of influenza with antiviral drugs in adults are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">
          "Seasonal influenza in children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7017.html" rel="external">
          "Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H939409">
         <span class="h1">
          INFLUENZA ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Information about influenza activity at the national, regional, and state level is available from the United States Centers for Disease Control and Prevention (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fweekly%2Findex.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLOtzxb%2BvTZhOOrHrvoZzklHTj9Wy66oSSp33vGFEDGR2rwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=132409" target="_blank">
          FluView interactive
         </a>
         ) and the World Health Organization (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Ftools%2Fflunet&amp;token=mr3MkQMxxRm373pPGLTYB3MJG4jrwa01SJKnzxLJ0iirSaC25i35un4SLoifVMRl&amp;TOPIC_ID=132409" target="_blank">
          FluNet
         </a>
         ). Surveillance information is updated regularly during influenza season.
        </p>
        <p>
         Local hospital or clinic laboratories may also collect information to monitor influenza activity in a specific geographic area.
        </p>
        <p>
         During the coronavirus 2019 (COVID-19) pandemic, influenza virus circulation has been low in the northern and southern hemispheres [
         <a href="#rid1">
          1
         </a>
         ]. The impact of the anticipated cocirculation of influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncertain.
        </p>
        <p class="headingAnchor" id="H1433467877">
         <span class="h1">
          CHEMOPROPHYLAXIS DECISION-MAKING
         </span>
        </p>
        <p class="headingAnchor" id="H3835160465">
         <span class="h2">
          Potential benefits and harms
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential benefits
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although chemoprophylaxis with neuraminidase inhibitors (
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         , laninamivir) or
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          baloxavir
         </a>
         decreases the risk of symptomatic laboratory-confirmed influenza compared with placebo (risk ratios ranging from 0.14 to 0.36) [
         <a href="#rid2">
          2,3
         </a>
         ], the absolute difference is small to modest (absolute difference of approximately 2 to 3 percent for individuals and 8 to 15 percent for households) [
         <a href="#rid3">
          3-6
         </a>
         ]. (See
         <a class="local">
          'Available antiviral agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         It is uncertain whether chemoprophylaxis prevents serious complications of influenza [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Available antiviral agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Trials of chemoprophylaxis with neuraminidase inhibitors were predominantly performed in healthy subjects; children with chronic conditions were generally excluded [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential harms
         </strong>
         – Potential harms of influenza chemoprophylaxis with antiviral drugs include [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Promotion of resistance to antiviral medications if chemoprophylaxis is used indiscriminately
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Neuraminidase inhibitor resistance is uncommon and occurs primarily in severely immunocompromised people who may have prolonged asymptomatic virus replication, although it has been reported among healthy children [
         <a href="#rid9">
          9-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          Baloxavir
         </a>
         resistance was reported among healthy subjects and subjects at increased risk for severe or complicated influenza in prelicensure clinicals of baloxavir treatment [
         <a href="#rid15">
          15,16
         </a>
         ]. Similarly, in a randomized trial comparing baloxavir with placebo for postexposure prophylaxis in immunocompetent household contacts, influenza viruses with mutations associated with reduced baloxavir susceptibility were detected in 4 percent of participants in the baloxavir group (some of whom were diagnosed at baseline before receiving baloxavir) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced availability of antiviral medications for the treatment of individuals who are severely ill or at high risk of influenza complications
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medication adverse effects (discussed below) (see
         <a class="local">
          'Available antiviral agents'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4015701764">
         <span class="h2">
          Alternatives to chemoprophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Widespread or routine chemoprophylaxis for influenza should be avoided [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Adjuncts and alternatives to chemoprophylaxis for the prevention of influenza in children at very high risk of severe or complicated influenza (eg, those who are severely immunocompromised) include [
         <a href="#rid17">
          17-19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunization of children at increased risk for severe or complicated influenza, their household contacts, and their out-of-home caregivers is preferred to chemoprophylaxis for the prevention of influenza. (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults", section on 'Whom to vaccinate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Immunization is the primary means of prevention of influenza infection in individuals ≥6 months of age, particularly those who at high risk for severe or complicated influenza  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ); chemoprophylaxis should not be substituted for immunization unless influenza immunization is specifically contraindicated [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Early treatment of exposed individuals is an alternative to chemoprophylaxis, although the two strategies have not been directly compared [
         <a href="#rid7">
          7,17
         </a>
         ]. For most children at very high risk of severe or complicated influenza (eg, those receiving chemotherapy), we suggest early treatment over chemoprophylaxis. Early treatment may reduce the use and/or duration of antiviral agents, lessening the risk of emergent resistance. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonpharmaceutical and behavioral interventions similar to those recommended during the coronavirus disease 2019 (COVID-19) pandemic (eg, avoidance of ill contacts, physical distancing, use of face masks, limited travel), which have been associated with decreased prevalence of influenza [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3131495712">
         <span class="h2">
          Other factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other factors in the decision whether to provide chemoprophylaxis for influenza include [
         <a href="#rid7">
          7,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of developing severe or complicated influenza for the patient or close contact of the patient (the risk is greatest in children who are severely immunocompromised).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The nature of the exposure (eg, duration, closeness of contact, other mitigation measures).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The timing of the exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Did it occur during the infectious period? The infectious period is typically one day before the onset of symptoms until 24 hours after resolution of fever, but it may be prolonged in immunocompromised individuals. (See
         <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">
          "Seasonal influenza in children: Clinical features and diagnosis", section on 'Transmission'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to administer prophylaxis within 48 hours of exposure (for postexposure prophylaxis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ability to complete the course of therapy (failure to complete therapy may contribute to the development of resistance).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advice from public health authorities and/or hospital epidemiologists.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H465163556">
         <span class="h1">
          OUTPATIENT SETTINGS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible indications
         </strong>
         — Neither postexposure nor pre-exposure prophylaxis is routinely recommended [
         <a href="#rid17">
          17
         </a>
         ]. Chemoprophylaxis of select children ≥3 months of age who are at very high risk of severe or complicated influenza (eg, those who are severely immunocompromised) or their close contacts is an alternative to early initiation of antiviral therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Children at increased risk for severe or complicated influenza
         </strong>
         – We make decisions about postexposure or pre-exposure chemoprophylaxis on a case-by-case basis in shared decision-making with the patient and/or caregivers for [
         <a href="#rid7">
          7,17
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Children at very high risk of severe or complicated influenza infection (eg, those who are severely immunocompromised) who have a contraindication to the influenza vaccine, are otherwise unable to receive the influenza vaccine, or may not respond to influenza vaccination.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Children at high risk of severe or complicated influenza  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) who have not been vaccinated for influenza or were vaccinated less than two weeks before exposure (for postexposure prophylaxis) or onset of influenza activity in the community (for pre-exposure prophylaxis).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Unvaccinated children who are eligible for the influenza vaccine should receive the influenza vaccine simultaneously [
         <a href="#rid7">
          7
         </a>
         ]. They should receive the
         <a class="drug drug_pediatric" data-topicid="12940" href="/z/d/drug information/12940.html" rel="external">
          inactivated influenza vaccine
         </a>
         (IIV) or recombinant influenza vaccine (RIV; if they are ≥18 years of age). (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Contacts of children at increased risk for severe or complicated influenza
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Postexposure prophylaxis – Postexposure chemoprophylaxis may be warranted for household contacts of children who are severely immunocompromised (eg, hematopoietic cell transplant recipients) if the household contact is unvaccinated against influenza and ≥3 months of age [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pre-exposure prophylaxis – Pre-exposure prophylaxis may be warranted for unvaccinated family members who are ≥3 months of age or unvaccinated health care providers who are likely to have ongoing close contact with children at very high risk of severe or complicated influenza who are unable to be vaccinated and unable to take chemoprophylaxis [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Unvaccinated contacts who are eligible for the influenza vaccine should receive the influenza vaccine simultaneously [
         <a href="#rid7">
          7
         </a>
         ]. They should receive IIV or RIV (if they are ≥18 years of age). (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postexposure prophylaxis regimens
         </strong>
         — Postexposure prophylaxis should not be initiated if exposure occurred ≥48 hours previously [
         <a href="#rid7">
          7,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Choice of agent
         </strong>
         – For postexposure prophylaxis in children, we prefer
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         (for those ≥5 years of age) based on viral surveillance and resistance data from recent influenza seasons  (
         <a class="graphic graphic_table graphicRef134112" href="/z/d/graphic/134112.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid24">
          24-26
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          Baloxavir
         </a>
         is also available for children ≥5 years of age [
         <a href="#rid27">
          27
         </a>
         ]. Doses are provided below and summarized in the tables  (
         <a class="graphic graphic_table graphicRef129898 graphicRef61888" href="/z/d/graphic/129898.html" rel="external">
          table 3A-B
         </a>
         ). (See
         <a class="local">
          'Available antiviral agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Laninamivir (not available in the United States) is available for postexposure prophylaxis in Japan.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="13045" href="/z/d/drug information/13045.html" rel="external">
          Peramivir
         </a>
         has not been studied for the prevention of influenza in children and is not indicted for chemoprophylaxis. Adamantane drugs should not be used for pre-exposure prophylaxis given high levels of resistance [
         <a href="#rid8">
          8,17,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initiation
         </strong>
         – Postexposure prophylaxis should be initiated as soon as possible after and within 48 hours of exposure [
         <a href="#rid7">
          7,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration
         </strong>
         – The duration of postexposure prophylaxis varies with the agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Oseltamivir or zanamivir –
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          Oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         should be administered until seven days after the last known exposure [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Baloxavir – Postexposure prophylaxis with
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          baloxavir
         </a>
         (for patients ≥5 years) consists of a single dose [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pre-exposure prophylaxis regimens
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Choice of agent
         </strong>
         – For pre-exposure prophylaxis, we prefer
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         (for those ≥5 years of age) based on viral surveillance and resistance data from recent influenza seasons  (
         <a class="graphic graphic_table graphicRef134112" href="/z/d/graphic/134112.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid24">
          24-26
         </a>
         ]. Doses are provided below and summarized in the tables  (
         <a class="graphic graphic_table graphicRef129898 graphicRef61888" href="/z/d/graphic/129898.html" rel="external">
          table 3A-B
         </a>
         ). (See
         <a class="local">
          'Available antiviral agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          Baloxavir
         </a>
         is not approved for pre-exposure prophylaxis [
         <a href="#rid27">
          27
         </a>
         ]. Given high levels of resistance, adamantane drugs should not be used for pre-exposure prophylaxis [
         <a href="#rid8">
          8,17,28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initiation
         </strong>
         – Pre-exposure prophylaxis should be initiated as soon as influenza activity is detected in the community [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Influenza activity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration
         </strong>
         – The duration for pre-exposure prophylaxis depends upon the indication.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Awaiting vaccine response – For individuals receiving chemoprophylaxis with
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         while awaiting the development of an immune response to the influenza vaccine, chemoprophylaxis is administered until 14 days after receipt of the influenza vaccine [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Other indications – For other indications, pre-exposure chemoprophylaxis with
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         should be administered every day for the duration of influenza activity in the community. Oseltamivir and zanamivir regimens as long as 16 weeks have been well tolerated [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1357539020">
         <span class="h1">
          INSTITUTIONAL OUTBREAK
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemoprophylaxis is one of multiple interventions to control outbreaks of influenza in a closed institutional setting with residents or patients at high risk of severe or complicated influenza (eg, long-term care facility, hospital rehabilitation unit, transplant unit) [
         <a href="#rid7">
          7,17
         </a>
         ].
        </p>
        <p>
         We use the definition for outbreak provided in the Infectious Diseases Society of America guidelines: ≥2 cases of health care-associated, laboratory-confirmed influenza among patients or residents of the same ward or unit within 72 hours [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential indications for chemoprophylaxis
         </strong>
         – In addition to other outbreak control measures (described below), potential target groups for chemoprophylaxis include [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic exposed residents/patients
         </strong>
         – For asymptomatic exposed residents/patients and residents/patients of outbreak-affected units (with or without known exposure), we suggest chemoprophylaxis, even if they have been vaccinated against influenza. Influenza transmission can occur rapidly in closed settings. Children with disabilities residing in long-term care facilities are at increased risk for influenza complications and mortality [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Chemoprophylaxis for institutional outbreaks of influenza is supported by randomized and observational studies in older patients) [
         <a href="#rid33">
          33-36
         </a>
         ] and observational studies in hospitalized children and neonates [
         <a href="#rid37">
          37-39
         </a>
         ]. In a cluster randomized trial, the influenza attack rate among nursing home residents was lower with influenza prophylaxis and treatment than with treatment alone (23 versus 35 percent) [
         <a href="#rid34">
          34
         </a>
         ]. Prophylaxis also reduced the mean duration of outbreaks (11 versus 24 days).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic exposed residents/patients
         </strong>
         – Exposed residents/patients who develop symptoms compatible with influenza or who are suspected to have influenza should undergo testing for influenza and receive antiviral therapy for influenza without waiting for test results. (See
         <a class="local">
          'Breakthrough infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In the setting of an institutional outbreak, there should be a low threshold for suspected breakthrough influenza infection. People with chronic illness who develop nosocomial infection may not have typical signs and symptoms; they may be nonverbal or unable to describe their symptoms [
         <a href="#rid7">
          7,40,41
         </a>
         ]. They may lack respiratory symptoms, have hypothermia rather than fever, or demonstrate behavioral changes [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Chemoprophylaxis should be resumed after treatment is completed if there is ongoing influenza exposure on the ward or unit [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Staff
         </strong>
         – Decisions regarding chemoprophylaxis for unvaccinated staff or staff who received influenza immunization with the
         <a class="drug drug_pediatric" data-topicid="12940" href="/z/d/drug information/12940.html" rel="external">
          inactivated influenza vaccine
         </a>
         or recombinant influenza vaccine in the two weeks before the outbreak should be made in consultation with hospital epidemiologists and/or public health authorities. Chemoprophylaxis for staff who received the
         <a class="drug drug_pediatric" data-topicid="12941" href="/z/d/drug information/12941.html" rel="external">
          live attenuated influenza vaccine
         </a>
         is discussed separately. (See
         <a class="local">
          'Receipt of LAIV'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of agent
         </strong>
         – For outbreak control in the institutional setting, we generally prefer
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         to other antiviral agents [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          Baloxavir
         </a>
         is an alternative for staff who receive chemoprophylaxis while awaiting a response to the influenza vaccine [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of chemoprophylaxis
         </strong>
         – The duration of prophylaxis in the institutional outbreak setting depends upon the indication.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exposed patients and residents – For exposed patients and residents,
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         should be administered for a minimum of two weeks and up to one week after the last known case was identified [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Awaiting vaccine response – For staff receiving chemoprophylaxis while awaiting the development of an immune response to the influenza vaccine, chemoprophylaxis with
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         is administered until 14 days after receipt of the influenza vaccine [
         <a href="#rid17">
          17
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          Baloxavir
         </a>
         prophylaxis is provided as a single dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other measures
         </strong>
         – Other measures for outbreak control include [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surveillance for new cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cohorting ill residents and staff members.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of facemasks by ill residents or patients and ill staff members.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Minimizing nonessential visits.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         (See
         <a class="medical medical_review" href="/z/d/html/6999.html" rel="external">
          "Infection control measures for prevention of seasonal influenza"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3154318078">
         <span class="h1">
          SPECIAL CIRCUMSTANCES
         </span>
        </p>
        <p class="headingAnchor" id="H2604995862">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Influenza chemoprophylaxis for pregnant people is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">
          "Seasonal influenza and pregnancy", section on 'Role of antiviral prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3359142879">
         <span class="h2">
          Receipt of LAIV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals immunized with the intranasal live-attenuated influenza vaccine (LAIV) should not receive chemoprophylaxis for 14 days after receipt of the LAIV because the vaccine strains are susceptible to antiviral drugs [
         <a href="#rid20">
          20
         </a>
         ]. Those who require chemoprophylaxis before the 14-day interval should be revaccinated with the
         <a class="drug drug_pediatric" data-topicid="12940" href="/z/d/drug information/12940.html" rel="external">
          inactivated influenza vaccine
         </a>
         or recombinant influenza vaccine (if ≥18 years of age).
        </p>
        <p class="headingAnchor" id="H3056567630">
         <span class="h2">
          Breakthrough infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who develop symptoms of influenza despite chemoprophylaxis should undergo testing for influenza and start antiviral therapy while awaiting results [
         <a href="#rid7">
          7
         </a>
         ]. Given the possibility of emergent resistance, particularly with
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          baloxavir
         </a>
         , children who develop symptoms of influenza during or after prophylaxis ideally should receive treatment with a different antiviral agent. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1088048187">
         <span class="h1">
          CHEMOPROPHYLAXIS COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Education of patients and/or caregivers of children who receive chemoprophylaxis should include the following information [
         <a href="#rid17">
          17,19,21
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For eligible children, immunization is the primary means of influenza prevention. (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chemoprophylaxis lowers, but does not eliminate, the risk of influenza. (See
         <a class="local">
          'Potential benefits and harms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Susceptibility to influenza returns with discontinuation of the antiviral medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals at increased risk of severe or complicated influenza  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) should seek medical evaluation if they develop a febrile respiratory illness or moderate to severe illness despite chemoprophylaxis so that they can receive antiviral therapy (See
         <a class="local">
          'Breakthrough infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1897623773">
         <span class="h1">
          AVAILABLE ANTIVIRAL AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pharmacology of antiviral agents is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H44960444">
         <span class="h2">
          Neuraminidase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuraminidase inhibitors prevent the release of virions from the host cell [
         <a href="#rid42">
          42
         </a>
         ]. Neuraminidase inhibitors are active against influenza A viruses and influenza B viruses [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1799798517">
         <span class="h3">
          Oseltamivir
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States,
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         is available for the prophylaxis of influenza in individuals ≥1 year of age, but it may be used in younger children when indicated [
         <a href="#rid17">
          17,43
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Route and dose
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          Oseltamivir
         </a>
         is generally administered orally. Limited data suggest that it may be administered by orogastric or nasogastric tube [
         <a href="#rid44">
          44,45
         </a>
         ], but the pharmacokinetics with enteric tube administration may be different than with oral administration, resulting in decreased concentrations of the active metabolite [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose of
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         varies according to age and weight.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Full-term infants &lt;1 year of age  (
         <a class="graphic graphic_table graphicRef129898" href="/z/d/graphic/129898.html" rel="external">
          table 3A
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Age &lt;3 months – Not recommended, except in critical situations (consultation with an specialist in pediatric infectious diseases is recommended)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Age 3 through 8 months – 3 mg/kg per dose once daily
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Age 9 through 11 months – 3.5 mg/kg per dose once daily
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If weight is not known, dosing should be determined by age as follows [
         <a href="#rid48">
          48
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Age 4 through 5 months – 17 mg once daily
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Age 6 through 11 months – 24 mg once daily
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 1 through 12 years  (
         <a class="graphic graphic_table graphicRef61888" href="/z/d/graphic/61888.html" rel="external">
          table 3B
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight ≤15 kg – 30 mg orally once daily
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight &gt;15 to 23 kg – 45 mg orally once daily
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight &gt;23 to 40 kg – 60 mg orally once daily
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weight &gt;40 kg – 75 mg orally once daily
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥13 years – 75 mg orally once daily
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In meta-analyses of randomized trials,
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         prophylaxis reduced the risk of symptomatic laboratory-confirmed influenza in exposed individuals (2.6 versus 5.6 percent; risk difference [RD] 3 percent, 95% CI 1.8-3.9; three trials, 2479 participants) and households (3.4 versus 17.0 percent; RD 13.6 percent, 95% CI 0.5-15.5; one trial 405 participants) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Nausea and vomiting are the most common adverse effects of
         <a class="drug drug_pediatric" data-topicid="12662" href="/z/d/drug information/12662.html" rel="external">
          oseltamivir
         </a>
         (occurring in 12 percent of recipients of once-daily dosing) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3632888736">
         <span class="h3">
          Zanamivir
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, dry powder
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         is available for the prophylaxis of influenza in individuals ≥5 years of age [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Route and dose
         </strong>
         – Dry powder
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         is administered by oral inhalation. Each inhalation is 5 mg. The recommended dose is two inhalations (10 mg total) once per day. Use of a dry powder inhaler requires high enough inspiratory flow to mobilize and aerosolize the medication. It is prudent to ask the child to demonstrate proper technique before prescribing zanamivir.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An intravenous (IV) form of
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         has been evaluated for prophylaxis in a clinical trial [
         <a href="#rid50">
          50
         </a>
         ]. The IV form is available in the United Kingdom and Europe but is not available in the United States [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In meta-analyses of randomized trials,
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         reduced the risk of symptomatic influenza in exposed individuals (1.2 versus 3.1 percent; RD 1.9 percent, 95% CI 1.0-2.5; four trials, 5275 participants) and households (4.1 versus 19.0 percent; RD 14.9 percent, 95% CI 12.2-16.6; two trials, 824 participants) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – In addition to gastrointestinal side effects,
         <a class="drug drug_pediatric" data-topicid="13079" href="/z/d/drug information/13079.html" rel="external">
          zanamivir
         </a>
         is associated with increased risk of bronchospasm in patients with a history of wheezing or chronic respiratory disease [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H182636264">
         <span class="h3">
          Laninamivir
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laninamivir is a long-acting inhaled neuraminidase inhibitor that is available for prevention of influenza in Japan [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Route and dose
         </strong>
         – Clinical trials of laninamivir used the following doses [
         <a href="#rid5">
          5,6
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 2 through 9 years – Single dose of 20 mg
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥10 years – A single dose of 40 mg or 20 mg daily for two days
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In a randomized trial, laninamivir (a single dose of 40 mg or 20 mg daily for two days) reduced laboratory-confirmed influenza among family members (≥10 years of age) of influenza patients who were within 48 hours of symptom onset (4.5 versus 12.1 percent in the placebo group) [
         <a href="#rid5">
          5
         </a>
         ]. Most of the patients with influenza had influenza A H3N2 infection. In a separate randomized trial, laninamivir (a single 20 mg dose) also reduced laboratory-confirmed influenza among family members between 2 and 10 years of age (11 versus 19 percent in the placebo group; relative risk reduction 46 percent, 95% CI 8-68) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2132893583">
         <span class="h2">
          Baloxavir
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          Baloxavir
         </a>
         blocks influenza proliferation by inhibiting initiation of mRNA synthesis [
         <a href="#rid54">
          54
         </a>
         ]. It has activity against influenza A and influenza B viruses.
        </p>
        <p>
         In Japan,
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          baloxavir
         </a>
         is licensed for postexposure prophylaxis of influenza in people ≥12 years and children &lt;12 years who weigh at least 20 kg. In the United States, it is licensed for postexposure prophylaxis in people ≥5 years of age [
         <a href="#rid54">
          54-57
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Route and dose
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          Baloxavir
         </a>
         is administered orally. The dose varies according to weight:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Weight &lt;20 kg (oral suspension) – 2 mg/kg orally as a single dose
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Weight 20 to &lt;80 kg (tablet or oral suspension) – 40 mg orally as single dose
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Weight ≥80 kg (tablet or oral suspension) – 80 mg orally as a single dose
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The efficacy of
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          baloxavir
         </a>
         for postexposure prophylaxis was demonstrated in a randomized trial that included 749 household contacts of 545 index patients with influenza who received antiviral therapy (53 percent with baloxavir) per standard practice in Japan [
         <a href="#rid3">
          3
         </a>
         ]. Baloxavir decreased the risk of laboratory-documented influenza in household contacts compared with placebo (1.9 versus 13.6 percent; adjusted risk ratio 0.14, 95% CI 0.06-0.30), without an increase in adverse effects. In subgroup analysis, baloxavir was effective in individuals at high risk for severe influenza and individuals who were unvaccinated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Emergent
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          baloxavir
         </a>
         resistance is the most important adverse effect of baloxavir. (See
         <a class="local">
          'Potential benefits and harms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other adverse effects of
         <a class="drug drug_pediatric" data-topicid="119538" href="/z/d/drug information/119538.html" rel="external">
          baloxavir
         </a>
         include diarrhea and vomiting, which occur in 2 to 6 percent of recipients [
         <a href="#rid15">
          15,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3147382774">
         <span class="h2">
          Adamantane drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13387" href="/z/d/drug information/13387.html" rel="external">
          Amantadine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12769" href="/z/d/drug information/12769.html" rel="external">
          rimantadine
         </a>
         are adamantanes (also called M2 inhibitors). Adamantanes target the M2 protein of influenza A, which forms a protein channel in the viral membrane that is essential for efficient viral replication. Adamantanes are not active against influenza B viruses.
        </p>
        <p>
         Circulating strains of influenza A virus have been widely resistant to adamantane drugs since 2009 and they are not recommended for prophylaxis of influenza [
         <a href="#rid8">
          8,28,59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4093558516">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111532.html" rel="external">
          "Society guideline links: Treatment and prevention of seasonal influenza with antivirals"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4065581612">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15369.html" rel="external">
          "Patient education: Flu (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/3992.html" rel="external">
          "Patient education: Influenza prevention (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4010.html" rel="external">
          "Patient education: Influenza symptoms and treatment (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H171391794">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemoprophylaxis decision-making
         </strong>
         – Influenza chemoprophylaxis decision-making for children at very high risk of severe or complicated influenza is individualized, considering:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The small to modest absolute benefit and potential harms, particularly development of antiviral resistance (see
         <a class="local">
          'Potential benefits and harms'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alternatives to chemoprophylaxis, including (see
         <a class="local">
          'Alternatives to chemoprophylaxis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Availability, suitability, and timing of influenza immunization, which is the primary means of preventing influenza infection
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Early initiation of antiviral therapy (as soon as possible after onset of symptoms)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For most children at very high risk of severe or complicated influenza, we suggest early initiation of antiviral therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); early treatment may reduce the use and/or duration of antiviral agents, lessening the risk of emergent resistance (see
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The potential for severe or complicated influenza in the child or child's contacts  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) and the nature and timing of exposure (see
         <a class="local">
          'Other factors'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemoprophylaxis in outpatient settings
         </strong>
         – Neither postexposure nor pre-exposure prophylaxis for influenza is routinely recommended for children in the outpatient setting. Possible indications for chemoprophylaxis of children who are at very high risk of severe or complicated influenza (eg, this receiving chemotherapy) or their close contacts as an alternative to early initiation of antiviral therapy are discussed above. (See
         <a class="local">
          'Outpatient settings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Institutional outbreak
         </strong>
         –
         <strong>
         </strong>
         Chemoprophylaxis is one of multiple interventions to control outbreaks of influenza in a closed institutional setting with patients at high risk of severe or complicated influenza (eg, long-term care facility, hospital rehabilitation unit, transplant unit). In this setting, we consider ≥2 cases of health care-associated, laboratory-confirmed influenza among patients or residents of the same ward or unit within 72 hours an outbreak.
         <strong>
         </strong>
         (See
         <a class="local">
          'Institutional outbreak'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For asymptomatic exposed residents/patients and residents/patients of outbreak-affected units (with or without known exposure), we suggest chemoprophylaxis, even if they have been vaccinated against influenza (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Influenza can spread rapidly in closed settings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Symptomatic patients should be tested for influenza infection and treated with antiviral therapy without waiting for the results. (See
         <a class="local">
          'Breakthrough infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Counseling
         </strong>
         – Patients and/or caregivers of patients who receive chemoprophylaxis should understand that (see
         <a class="local">
          'Chemoprophylaxis counseling'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunization is the primary means of influenza prevention. (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemoprophylaxis does not eliminate the risk of influenza. (See
         <a class="local">
          'Potential benefits and harms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Susceptibility to influenza returns with discontinuation of prophylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals at high risk of severe or complicated influenza  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) should seek medical evaluation if they develop symptoms of influenza so they can receive antiviral therapy. (See
         <a class="local">
          'Breakthrough infection'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          World Health Organization. Recommended composition of influenza virus vaccines for use in the 2022 southern hemisphere influenza season. September 24 2021. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-southern-hemisphere-influenza-season (Accessed on October 15, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011; 62:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med 2020; 383:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; :CD008965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashiwagi S, Watanabe A, Ikematsu H, et al. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza. Clin Infect Dis 2016; 63:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakano T, Ishiwada N, Sumitani T, et al. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Memoli MJ, Athota R, Reed S, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014; 58:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis 2020; 39:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roosenhoff R, Reed V, Kenwright A, et al. Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clin Infect Dis 2020; 71:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; 20:1204.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on August 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyeki TM. Influenza. Ann Intern Med 2017; 167:ITC33.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Influenza. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.447.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COMMITTEE ON INFECTIOUS DISEASES. Recommendations for Prevention and Control of Influenza in Children, 2022-2023. Pediatrics 2022; 150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen SJ, Winn AK, Budd AP, et al. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep 2021; 70:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng L, Zhang T, Wang Q, et al. Impact of COVID-19 outbreaks and interventions on influenza in China and the United States. Nat Commun 2021; 12:3249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garten R, Blanton L, Elal AIA, et al. Update: Influenza Activity in the United States During the 2017-18 Season and Composition of the 2018-19 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 2018; 67:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu X, Blanton L, Elal AIA, et al. Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 2019; 68:544.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Influenza Antivral Drug Resistance. https://www.cdc.gov/flu/treatment/antiviralresistance.htm (Accessed on September 15, 2020).
         </li>
         <li class="breakAll">
          Xofluza (baloxavir marboxil) prescribing information. US Food and Drug Administration (FDA) approved product information. Revised August 2022. Available online at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (Accessed on August 16, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morb Mortal Wkly Rep 2012; 61:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khazeni N, Bravata DM, Holty JE, et al. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009; 151:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anekthananon T, Pukrittayakamee S, Ratanasuwan W, et al. Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks. J Antimicrob Chemother 2013; 68:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rainwater-Lovett K, Chun K, Lessler J. Influenza outbreak control practices and the effectiveness of interventions in long-term care facilities: a systematic review. Influenza Other Respir Viruses 2014; 8:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor G, Mitchell R, McGeer A, et al. Healthcare-associated influenza in Canadian hospitals from 2006 to 2012. Infect Control Hosp Epidemiol 2014; 35:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005; 6:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booy R, Lindley RI, Dwyer DE, et al. Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial. PLoS One 2012; 7:e46509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ye M, Jacobs A, Khan MN, et al. Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis. BMJ Open 2016; 6:e011686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merritt T, Hope K, Butler M, et al. Effect of antiviral prophylaxis on influenza outbreaks in aged care facilities in three local health districts in New South Wales, Australia, 2014. Western Pac Surveill Response J 2016; 7:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinjoh M, Takano Y, Takahashi T, et al. Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection. Pediatr Infect Dis J 2012; 31:1119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsagris V, Nika A, Kyriakou D, et al. Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit. J Hosp Infect 2012; 81:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pannaraj PS, Tam B, Akan D. Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. J Perinatol 2011; 31:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khandaker G, Rashid H, Zurynski Y, et al. Nosocomial vs community-acquired pandemic influenza A (H1N1) 2009: a nested case-control study. J Hosp Infect 2012; 82:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Dool C, Hak E, Wallinga J, et al. Symptoms of influenza virus infection in hospitalized patients. Infect Control Hosp Epidemiol 2008; 29:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343:1778.
          </a>
         </li>
         <li class="breakAll">
          Tamiflu (oseltamivir phosphate) prescribing information. www.gene.com/download/pdf/tamiflu_prescribing.pdf (Accessed on August 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giraud C, Manceau S, Oualha M, et al. High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit. Antimicrob Agents Chemother 2011; 55:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang Girdwood SC, Mizuno T, Krallman KA, et al. Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children. Pediatr Infect Dis J 2019; 38:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wildschut ED, de Hoog M, Ahsman MJ, et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One 2010; 5:e10938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 2011; 128:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616.
          </a>
         </li>
         <li class="breakAll">
          Dectova (zanamivir). European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/dectova. (Accessed on September 29, 2020).
         </li>
         <li class="breakAll">
          Electronic medicines compendium. Dectova solution for infusion. https://www.medicines.org.uk/emc/product/10193/smpc#gref (Accessed on September 29, 2020).
         </li>
         <li class="breakAll">
          Relenza (zanamivir inhalation powder). United States Prescribing Information. Revised June, 2018. US Food &amp; Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on March 11, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heo YA. Baloxavir: First Global Approval. Drugs 2018; 78:693.
          </a>
         </li>
         <li class="breakAll">
          Shionogi press release. XOFLUZA (Baloxavir marboxil) tablets 10 mg/20 mg for the treatment of influenza types A and B launched in Japan. http://www.shionogi.co.jp/en/company/news/2018/pmrltj0000003oid-att/e180314.pdf (Accessed on October 24, 2018).
         </li>
         <li class="breakAll">
          Xofluza (baloxavir marboxil) for oral use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210854s001lbl.pdf (Accessed on October 17, 2019).
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA expands approval of influenza treatment to post-exposure prevention. https://www.fda.gov/news-events/press-announcements/fda-expands-approval-influenza-treatment-post-exposure-prevention (Accessed on November 24, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker J, Block SL, Matharu B, et al. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J 2020; 39:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 132409 Version 8.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-southern-hemisphere-influenza-season" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : World Health Organization. Recommended composition of influenza virus vaccines for use in the 2022 southern hemisphere influenza season. September 24 2021. https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-southern-hemisphere-influenza-season (Accessed on October 15, 2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20950645" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32640124" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24718923" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27118785" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940664" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30566567" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21248682" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19745803" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9780244" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24186906" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20415572" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32056049" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Influenza and antiviral resistance: an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31560055" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30184455" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32526195" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32526195" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28869984" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28869984" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34448800" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36065750" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Recommendations for Prevention and Control of Influenza in Children, 2022-2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34292924" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34059675" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Impact of COVID-19 outbreaks and interventions on influenza in China and the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29879098" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Update: Influenza Activity in the United States During the 2017-18 Season and Composition of the 2018-19 Influenza Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31220057" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31220057" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31220057" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22672977" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652173" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23143901" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24373292" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Influenza outbreak control practices and the effectiveness of interventions in long-term care facilities: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24442080" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Healthcare-associated influenza in Canadian hospitals from 2006 to 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16286056" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23082123" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treating and preventing influenza in aged care facilities: a cluster randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27381211" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Evaluation of the use of oseltamivir prophylaxis in the control of influenza outbreaks in long-term care facilities in Alberta, Canada: a retrospective provincial database analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27757249" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effect of antiviral prophylaxis on influenza outbreaks in aged care facilities in three local health districts in New South Wales, Australia, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22634596" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22463979" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Influenza A/H1N1/2009 outbreak in a neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233797" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22944361" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Nosocomial vs community-acquired pandemic influenza A (H1N1) 2009: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18462143" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Symptoms of influenza virus infection in hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11114318" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prevention and treatment of influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11114318" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Prevention and treatment of influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20159892" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20937783" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31738337" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20532176" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21890834" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Recommendations for prevention and control of influenza in children, 2011-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10536125" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10390212" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10390212" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10390212" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10390212" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29623652" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Baloxavir: First Global Approval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29623652" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Baloxavir: First Global Approval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29623652" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Baloxavir: First Global Approval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29623652" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Baloxavir: First Global Approval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32516282" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21148489" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Emerging influenza antiviral resistance threats.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
